# Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion.

- **DOI:** [10.2147/opth.s116343](https://doi.org/10.2147/opth.s116343)
- **Rating:** Sound (3.1 out of 5)
- **Verdict:** A practical pilot for low-cost RVO therapy, but its nine-eye uncontrolled design keeps efficacy claims preliminary.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-07-02
- **Evaluation page:** https://www.nabu.science/paper/10.2147%2Fopth.s116343

## Strengths

- **Prospective registered pilot design** The Methods describe a prospective two-center study with IRB approval, written informed consent, monthly follow-up, and clinical trial registration. This gives the case series more procedural transparency than a retrospective report.
  - Dimension: methodological rigour
  - Location: Methods, first paragraph; Clinical Evaluations and Treatments
- **Clear anatomic outcome reporting** The Results report a substantial decrease in mean CMT at 1 and 4 months with P-values, while also reporting that BCVA did not improve significantly. This separates the anatomic signal from the weaker functional outcome.
  - Dimension: reporting
  - Location: Results, Visual Acuity; Results, Macular Thickness
- **Concrete affordability rationale** The Discussion explains why aflibercept access is limited in some countries and compares the per-vial costs of ziv-aflibercept, aflibercept, and bevacizumab. That creates a clear real-world motivation for studying the intervention.
  - Dimension: application pathway
  - Location: Discussion, affordability paragraphs

## Limitations

- **Nine-eye uncontrolled evidence base** The study has no comparator arm and includes only nine eyes, so the observed CMT improvement cannot be separated from regression to the mean, natural disease fluctuation, or residual effects of prior therapies.
  - Dimension: methodological rigour
  - Location: Methods, study design; Results, Baseline Characteristics
- **Heterogeneous RVO and treatment histories** The cohort pools five CRVO and four BRVO eyes despite different disease characteristics, and prior injections ranged from 2 to 24 with last treatment 1 to 63 months before enrollment. This limits attribution of response to ziv-aflibercept and weakens subgroup inference.
  - Dimension: methodological rigour
  - Location: Results, Baseline Characteristics; Discussion, strengths and weaknesses paragraph
- **Clinical-use language outruns design** The Discussion says the data support use in selected RVO patients, but the paper itself acknowledges the small cohort, mixed composition, and brief endpoint. That phrasing is stronger than the evidence can sustain.
  - Dimension: reporting
  - Location: Discussion, final paragraph

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The main numerical results are broadly coherent, with only a trivial abstract/results CMT rounding difference. The Discussion includes efficacy-supportive language that exceeds what a small single-arm heterogeneous pilot can establish.
- **Research conduct:** Noted. The paper declares IRB approval at two institutions, Declaration of Helsinki adherence, written informed consent, and trial registration. No data/code availability statement or visible conflict-of-interest statement is reported in the supplied text.
- **Reference integrity:** Clean. All 27 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17